The Henryk Niewodniczański Institute of Nuclear Physics Polish Academy of Sciences (IFJ PAN)’s Post

We are thrilled to announce the publication of our pilot study titled **"Exploring the Potential Value of [68Ga]Ga-FAPI-46 PET-CT for Molecular Assessment of Fibroblast Activation in Interstitial Lung Disease: A Single-Center Pilot Study" in **Clinical Nuclear Medicine**. In our study, we aimed to assess the association between high-resolution #computed_tomography (#HRCT) findings and #pulmonary fibrotic activity using [68Ga]Ga-FAPI PET/CT in patients with interstitial lung disease (#ILD). Additionally, we explored the efficacy of combining [68Ga]Ga-FAPI-46 PET/CT with 99mTc-MIBI SPECT/CT for evaluating fibrosis and inflammation in ILD. Key highlights from our findings: - Our results included 20 ILD patients, revealing significant differences in multiple PET-derived parameters compared to a control group. - There was a notable correlation between HRCT fibrosis scores and several PET metrics, highlighting the potential of these imaging modalities in assessing fibrotic activity. - Interestingly, we also identified intense FAPI uptake in the gallbladder among ILD patients, an observation not found in the control group. Our conclusion suggests that the integrated use of [68Ga]Ga-FAPI PET/CT and 99mTc-MIBI SPECT/CT may provide greater insights into the complex pathology of ILD, enhancing our understanding of fibrotic activity driven by fibroblasts and the inflammatory processes at play. We are excited about the implications of our work in advancing the molecular assessment and management of ILD! 🔗 https://lnkd.in/giQtrxJN #InterstitialLungDisease #FAPI #ILD #NuclearMedicine #PETCT #Fibrosis #ClinicalNuclearMedicine #MedicalImaging #PGNMRC

MinFound Medical oncology solution features two PET/CT systems, with excellent characteristics for various requirements, including cardio; and a wide aperture multi-modality CT scanner ScintCare e580-R. Nuclear medicine is a rapidly evolving field worldwide, with advancements in diagnostic imaging and therapeutic treatments. Collaboration between science, industry, and healthcare providers is driving innovation in nuclear medicine, with a focus on personalized medicine and targeted therapies. #molecularimaging #digitalpetct #SiPMdetector #PETdigitalgating #PETcalibration #oncologydiagnostics #imagingbeyondinfinity

Adaptive proton therapy is taking a big step forward, and I’m excited about what this means for patient care! By integrating diagnostic-quality CT into the treatment workflow, we verify patient anatomy daily and ensure that the treatment plan stays on track. And with AI capabilities and automated decision-making processes, adaptive therapy is no longer a concept—it's becoming a reality. This breakthrough means that proton therapy is not just the safest form of radiation therapy, but with these advancements, it will become even more efficacious for a wider range of diseases. It’s all about combining beam precision with real-time navigation, and we’re just scratching the surface of its potential. Curious to learn more? #ProtonTherapy #AdaptiveTherapy #HealthcareInnovation #AIInMedicine #CancerCare #PrecisionMedicine #RadiationTherapy #PCure American Society for Radiation Oncology (ASTRO) AAPM Student and Trainees Subcommittee European Society for Radiotherapy and Oncology (ESTRO) PTCOG-NA The National Association for Proton Therapy Elekta Varian RaySearch Laboratories Siemens Healthineers Philips P-Cure Ltd Aron Popovtzer Philip Blumenfeld Jon Feldman Marcel Fang

Whole-body SPECT imaging is a powerful diagnostic tool that combines functional and anatomical information to provide detailed insights into the entire body. It is particularly valuable in detecting and monitoring diseases such as metastatic cancer, bone disorders, and certain neurological conditions. This imaging modality uses radiotracers to highlight areas of abnormal metabolic activity, helping clinicians make accurate diagnoses and guide targeted treatments. The ability to visualize functional changes at a molecular level makes SPECT a cornerstone in personalized medicine. Excited to continue exploring the advancements in nuclear medicine and their impact on patient care! 🚀 #NuclearMedicine #SPECT #WholeBodyScan #MedicalImaging #ProfessionalGrowth

Did You Know? The Story of Iodine-131 🧬 Discovered over 80 years ago in 1938, Iodine-131 has remained a cornerstone of modern nuclear medicine. This radioactive isotope has been a game-changer, particularly in treating thyroid disorders, such as hyperthyroidism and thyroid cancer. But how does it work? 🤔 Once administered, Iodine-131 travels directly to the thyroid, where it emits radiation to selectively destroy overactive or cancerous thyroid cells. This precision allows for targeted treatment, reducing the need for invasive surgery and minimizing side effects. ✨ 🌟 Still in Use Today: Fast forward to today, and Iodine-131 is still widely used around the world, proving its lasting impact on healthcare. It’s trusted by physicians because of its effectiveness, safety, and ability to provide long-term results. From shrinking overactive thyroids to eradicating cancer cells, this small but powerful isotope continues to save lives. 🌍 A Global Legacy: Used in hospitals and clinics globally, Iodine-131 remains a prime example of how early scientific breakthroughs continue to drive modern medicine forward. Its applications have expanded, and it now helps millions of people lead healthier lives with fewer complications. From 1938 to 2024, Iodine-131’s story is one of longevity, innovation, and healing. It’s amazing how a discovery from decades ago continues to play such a critical role in thyroid health today! 🙌 #Iodine131 #ThyroidHealth #NuclearMedicine #ThyroidTreatment #Radiopharmaceuticals #MedicalInnovation #FunFactFriday #HealthcareRevolution #IMS

Our customers mean the world to us, and this standout moment from 2024 is another great example of why! The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Podcast Series offers engaging, relevant content to members and the nuclear medicine and molecular imaging community. Their most recent podcast highlights the commendable work one of our customers, CMIT (The Center for Molecular Imaging and Therapy) focuses on - advancing molecular imaging technologies and radiopharmaceutical research. Based in Shreveport, Louisiana, CMIT collaborates with healthcare providers and researchers to develop novel diagnostic and therapeutic techniques. Its work includes PET/CT imaging utilizing United Imaging's Digital High-Resolution PET/CT uMI Panorama™ for cancer, neurological, and cardiac conditions. The center aims to enhance patient care by improving disease diagnosis and treatment. Listen here: https://ow.ly/tjW050Uy2J6

Image-Guided Radiation Therapy Market worth $2.4 billion by 2028 Download PDF Brochure:-https://lnkd.in/d2Jfkxxx The global image-guided radiation therapy market in terms of revenue was estimated to be worth $1.9 billion in 2023 and is poised to reach $2.4 billion by 2028, growing at a CAGR of 5.2% from 2023 to 2028. Image-guided Radiation Therapy Market: Market Dynamics ✅ Driver: Increase in non-invasive cancer treatments through radiation therapy ✅ Restraint: The dearth of skilled radiologist/oncologist ✅ Opportunity: Rising healthcare expenditure across developing countries ✅ Challenges: Availability of alternative technology 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Siemens Healthineers Elekta Accuray GE HealthCare Vyaire Medical, Hitachi #ImageGuidedRadiationTherapy #CancerTreatment #RadiationOncology #MedicalImaging #PrecisionMedicine

As part of the ENETS Advisory Board and Theranostics Task Force, I am grateful for the opportunity to contribute to this recent paper titled "Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force" published in the Journal of Neuroendocrinology. This consensus report addresses the complex challenges in developing standardized response evaluation criteria for peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors (NETs). I invite you to read the full article and explore the key insights that will help shape the future of PRRT and improve patient care in NETs. #PRRT #NeuroendocrineTumors #ENETS #Theranostics #RadiationTherapy #CancerResearch #NETs #MedicalResearch #PatientCare #Collaboration

Check out our newly updated course; Neuroendocrine Tumour Imaging and Molecular Radiotherapy. Intended for radiologists and nuclear medicine physicians, this eLearning course aims to explore the diverse group of these relatively rare cancers. Course Highlights👇 🔷explore the concept of somatostatin receptor imaging 🔷examine the clinical indications for performing 68 Ga DOTA-SSA PET-CT and its use in evaluating recurrence 🔷deep dive into the role of 18FDG PET-CT in high and low-grade NETs 🔷advance your expertise and improve patient outcomes To register 👉 https://bit.ly/NETsImaging Our courses are available to Alliance Medical Ltd and #NHS NC1 Staff. #neuroendocrine #NETsCancer #radiologist #PETCT

Selfies with Celebs, Now with Yigal Livne Meeting Yigal recently was a reminder of how much impact one person’s vision and skill can have on an entire field. Yigal designed the first image-guided positioning system for treating patients with protons in a seated position. (Thank you Oren Arad, Danny Ellenbogen, Yael Braude, Yaron Anaki, and others 🙂, too.) That system was installed at Northwestern Medicine, marking a pivotal moment in the shift towards a compact, gantry-less approach in proton therapy. Back then, we were just beginning to explore what was possible. Today, P-Cure has grown into a provider of fully FDA-cleared systems, with manufacturing capabilities that can support global demand. But when I think back to Yigal’s original design, it still feels like the heartbeat of our journey. What stood out during our conversation wasn’t just the technical genius of that design, but the idea it represented—patient care at the center, always. It’s that same principle that continues to drive the evolution of particle therapy, bringing it closer to becoming mainstream clinical practice. This meeting wasn’t just a trip down memory lane; it was a chance to reflect on where we started, how much we’ve grown, and how innovation like Yigal’s continues to shape the future. I’m grateful for people like him who dare to think differently and build solutions that truly make a difference. #Gratitude #ProtonTherapy #Innovation #EngineeringWithPurpose American Society for Radiation Oncology (ASTRO) European Society for Radiotherapy and Oncology (ESTRO) AAPM Student and Trainees Subcommittee P-Cure Ltd Philips Elekta Varian Siemens Healthineers Hadassah Medical Center Sharett Oncology Institute Aron Popovtzer Jon Feldman Philip Blumenfeld Marcel Fang